Drug intelligence / Profile preview

MNKD-101

Development stage
Discontinued
Lead developer
Mannkind
Modality
Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Inhalation
01

Overview

MNKD-101 is an investigational inhaled formulation of clofazimine, developed as a clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease, particularly infections caused by Mycobacterium avium complex (MAC). Clofazimine is an antibiotic that inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. The inhaled delivery aims to provide high drug concentrations directly in the lungs while minimizing systemic toxicity and side effects associated with oral administration. MNKD-101 has received Orphan Drug, Qualified Infectious Disease Product (QIDP), and Fast Track designations from the FDA for pulmonary NTM infections. It is currently being evaluated in a global Phase 3 clinical trial (ICoN-1) as an add-on to guideline-based therapy in adults with refractory NTM lung disease[1][2][5][7][8].

Other names
clofazimine inhalation suspension

Beyond the preview

Go deeper on MNKD-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNKD-101.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call